Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease

Trial Profile

Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Loxapine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2010 Valeant Pharmaceuticals have announced in a media release that the US FDA have said in a Complete Response Letter that they have a clinical safety concern related to data from this study and two other phase I pulmonary safety studies.
    • 02 Sep 2009 Planned number of patients changed from 50 to 53 as reported by ClinicalTrials.gov.
    • 29 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top